Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic CIK Cells After Non-Myeloablative Transplant for MDS/MPD
NCT01392989Phase 2Completed
- Start
- Mar 2011
- Primary completion
- Jun 2016
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of unmodified CIK in myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), myeloid neoplasms. Started Mar 2011; status: completed.
02
Drugs
unmodified CIK
03
Conditions
myelodysplastic syndrome (MDS)myeloproliferative neoplasms (MPN)myeloid neoplasms
Beyond the preview
Go deeper on NCT01392989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01392989.